Tumor-infiltrating lymphocytes (TILs) have shown in vivo antitumor efficacy in both animal and human studies. Functions thought necessary for antitumor activity include cytolysis, homing, and proliferation at tumor sites. TILs, which are T lymphocytes grown ex vivo directly from tumors, bear interleukin 2 (IL-2) receptors capable of transducing the IL-2 mitogenic signal. However, IL-2 is not normally synthesized by solid tumor cells. This study was aimed at exploring the possible presence of T-cell mitogens of tumor origin. To this end four TIL lines derived from four melanoma patients were studied for their ability to use the environments of cultured tumor cell lines as mitogenic sources. The presence of four irradiated cultured human tumor cell lines, three of which were derived from the same melanoma patients as the TILs, were found to stimulate proliferation of human TILs in the absence of IL-2. Further investigation showed that the observed proliferative stimulation by the fourth tumor line was due to secreted factor(s) as mitogenic activity was present in the serum-free tumor cell supernatant. Both immunologic analyses of this medium and proliferative assays in which TILs were stimulated with recombinant lymphokine standards suggest the presence of a yet uncharacterized T-cell mitogen.
The idea that the tumor environment is intrinsically immunogenic and, therefore, contains lymphocytes with the potential to induce tumor regression has led to the use of tumor-infiltrating lymphocytes (TILs) in clinical trials (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . In this procedure lymphocytes are grown ex vivo directly from tumors in the presence of the lymphokine interleukin 2 (IL-2); patients are reinfused with their TILs after the latter have been expanded in culture for several weeks. Although 60% of metastatic melanoma patients who had not previously received any immunotherapy showed objective responses in the largest clinical TIL trial to date (15) , the characteristics of the tumor environment that produces TILs in vivo remain unclear.
Two classes of stimuli-one derived from cell-cell contact between tumor cells and immunocytes and the other from soluble factors-may influence T-cell homing and proliferation. IL-2 is a potent mitogen for T cells, the cell type of TILs used (Table 1) ; however, its biosynthesis appears to be confined to immunocytes (16) . This fact is consistent with the current belief that immunologically competent cells such as lymphocytes and monocytes represent the major sources of secreted mitogenic stimulation for lymphocytes. In this study the subject of soluble factors secreted by tumor cell lines as sources of stimuli for lymphocyte proliferation was addressed.
As a starting point for this work, the issue of whether a tumor cell line established from a melanoma tumor could stimulate the growth of TILs derived from melanoma masses was examined. After confirming the amplification potential of three melanoma cell lines, a nonmelanoma line was tested for the same bioactivity and found to be at least as potent a mitogenic source; tumor-derived mitogenic activity for TILs could be ascribed to secreted factor(s) as mitogenic activity for TILs was found in its serum-free supernatant. Immunologic and proliferative assays indicate nonidentity of at least one secreted factor with any previously characterized lymphokine. The serum-free medium (SFM) used for proliferation assays was a modification of a serum-free medium used for melanoma cells (18) with DMEM/Ham's F-12 at a 1:1 ratio substituting for DMEM alone.
MATERIALS AND METHODS

Materials
The bioreactor cartridge was seeded with -5 x 109 A-431 cells in DMEM/10% FCS. After 3 weeks, the medium in the extracapillary space (ECSM) of the cartridge was switched to the SFM and the FCS concentration in the reservoir medium was lowered from 10% to 2%. The ECSM was drained daily from the cartridge, which was then filled with fresh SFM. The conditioned medium (ECSM) was then centrifuged, filtered and with a confluent monolayer of 618 tumor cells. Twenty-four hours later the cultures were examined and photographed. In the former, lymphocytes grow as large clusters, whereas in the latter cellular heterophilia-i.e., adhesion between lymphocytes and tumor cells-predominates over cellular homophilia-i.e., adhesion among lymphocytes. Although TILs 618, 660, and 677 could lyse autologous tumor cells that had been frozen but never cultured, they showed virtually no lytic capability against any of the cultured tumor lines in the configuration used in this study-i.e., as adherent monolayers. This sharply contrasts with lymphokine-activated killer cells, which effectively lysed all tumor lines used in this work.
(X110.) history of IL-2 dependence, the initial set of experiments was done in the presence of IL-2 (1000 and 2 units/ml) as well as in its absence. As seen in Fig. 2a pendent of serum factors, proliferation assays were done in parallel in SFM and DMEM/10% FCS. Fig. 3 TILs crest, cells ofa line not derived from this embryologic origini.e., the A-431 cell line, which was originally derived from an epidermal carcinoma, were tested for ability to potentiate TIL proliferation in both serum-containing and serum-free media. Fig. 3 shows that irradiated A-431 cells potentiated proliferation of all four TIL lines in serum (Fig. 3a) and showed effects similar to 618 tumor cells in SFM (Fig. 3b) cartridge in cross section (Fig. 4) . Tumor cells were only seen in the space outside the hollow fibers. The membrane lining these fibers had a molecular mass cutoff of 10 kDa; hence, any factors secreted by the tumor cells with a molecular mass >10 kDa were retained in the ECSM. The medium that circulated inside the hollow fibers was composed of DMEM/ 2% FCS and was designated as the reservoir. The ECSM was drained daily and assayed for bioactivity.
Rates of [3H]thymidine incorporation into both 618 and 660 TILs as a function of increasing concentrations of ECSM are plotted in Fig. Sa . There is a dose-dependent increase in proliferative activity up to the assay composition of 50% ECSM for both 618 and 660 TILs. Above this level both curves fall off. These declines may be due to the absence of nutrients in the spent ECSM or the presence of inhibitory factor(s). Additionally, these curves may also represent behavior similar to that of other known mitogens, for which at high concentrations proliferative levels are submaximal. In support of the latter hypothesis-when partially purified material was used as the stimulus, the dose-response curve was U-shaped with the maximum observed at -1 mg of protein per ml (data not shown). Thus, molecular mass of the mitogenic factor(s) must be, at least, 10 kDa as no mitogenic activity was associated with factor(s) secreted into the reservoir.
Is the Secreted Activity Due to Known T-CelI Mitogens? To determine whether the mitogenic activity present in ECSM was due to factors that have previously been shown to have direct mitogenic activity for T cells, three ECSM samples collected at 2-week intervals were tested for IL-2, IL-4, and IL-6 by ELISA.
The presence of neither IL-2 (using kits from the two indicated companies) nor IL-4 was measurable at or above detection levels for these two lymphokines-i.e., 0.4 Cetus unit per ml and 90 pg/ml, respectively. At these two respective concentration levels no significant proliferative activity above background was detected. However, IL-6 was found to be present at 2 ng/ml; the presence of IL-6 in A-431 cell supernatants has been reported (19 Proc. Natl. Acad. Sci. USA 87 (1990) To ascertain whether IL-6 could be a mitogen for TILs under the conditions used in this study (3H]thyMridine incorporation was measured after culturing 660 TILs for 24 hr in the presence of IL-6 at concentrations ranging from 0.01 to 20 ng/ml; no [3H]thymidine incorporation above background was measured. Furthermore, the presence of a neutralizing monoclonal antibody against IL-6 had no effect on the stimulation of [3H]thymidine incorporation induced by ECSM, whereas mitogenic stimulation by IL-2 standards up to 100 units/ml was completely inhibited by the anti-IL-2 antibody used.
Lack of mitogenic activity' for 660 TILs was also seen for TGF-pS (1 x 10-7,-8,-9,-10,-11, and 12 M) and TNF-a (1, 10, and 100 ng/ml). In all experiments IL-2 and ECSM served as positive controls. DISCUSSION The idea that the tumor environment contains lymphocytes that may exhibit antitumor activity was the basis for using lymphocytes expanded'in culture as' therapeutic agents (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Much work supports the'concept that an immune response is initiated against tumors via direct tumor celllymphocyte contact, followed by the secretion of factors mitogenic for lymphocytes from several immunocyte sources. However, the possibility of tumor cells providing a mitogenic stimulus for lymphocytes in the form of secreted factors has not been well explored. Thus, the objective of this work was to determine whether tumor cells could secrete factor(s) mitogenic for lymphocytes. (Fig. lb) . To determine whether the observed apposition between TILs and tumor cells was part of an immunostimulatory environment, proliferation of four TIL lines was compared in the presence and absence of irradiated tumor cells. In the presence of IL-2 addition of irradiated culture-618 tumor cells did not significantly affect mitosis of the four TIL lines tested (Fig.  2a) . However, in the absence of IL-2 (Fig. 2b ) these tumor cells dramatically increased the proliferation rates of two TIL lines, 618 and 660, and increased less significantly the rate of a third, 677. Thus, cultured tumor cells can support T-cell mitogenesis independently' of IL-2. This fact may be essential in understanding'the observed disparity in phenotypic profiles of TIL cultures at the stage of reinfusion into patients with those of the starting populations (15, 20) . That is, because receptors for IL-2 are present on virtually all activated T cells (21) , the T-cell population that will grow ex vivo in the constant presence of this lymphokine is strongly biased toward those cells capable of transducing and using the IL-2 signal most efficiently. Hence, factors from the tumor environment, which may be essential for maintenance of lymphocytes with antitumor activity, may not be retained in long-term cultures in which all tumor cells have died and the only exogenous cytokine is the pan-T-cell mitogen IL-2.
In the present study the observed mitogenic stimulation of TILs by irradiated tumor cells was shown to be of cellular origin and not from the serum, as indicated by Fig. 3 . In addition to the tumor line established from patient 618, data in Table 1 show-that tumor lines from two other melanoma patients, 677 and 660, were similar in their ability to enhance proliferation of 660 TILs in SFM. Thus, the presently reported mitogenic T-cell stimulation by tumor cell lines, all of which were derived from'unrelated patients, is clearly not major histocompatibility complex-restricted.
To determine whether tumor cell-induced lymphocyte mitogenicity is characteristic of tumors of a specific embryonic origin, such as the neural crest, which includes melanomas as well as neuroblastomas, a cell line derived from a tumor of epidermal carcinoma origin, the A-431 line was used as a source of potentiation of TIL proliferation. Data indicating that A-431 cells can serve as a superior mitogenic source for TILs in serum (Fig. 3a) and equivalently to the 618 melanoma line in SFM (Fig. 3b) suggest that this type of immunocyte stimulation may be broadly prevalent.
Proof that activity mitogenic for TILs is secreted by A-431 cells was confirmed by the activity in the ECSM (Fig. Sa) . These dose-response curves indicate the presence of cytokines that exhibit behavior similar to that of other known mitogens, where submaximal proliferative levels have been measured at high concentrations. The absence of IL-2 and IL-4 by ELISA and the lack ofproliferative stimuli from IL-6, TNF-a, and TGF-,f under the experimental conditions used suggest the presence of a direct T-cell mitogen not previously characterized.
In conclusion, tumor cell lines can increase the proliferative potential of TILs in the absence of IL-2. The molecule(s) responsible for this activity may be essential components of the biochemical basis of immunogenicity observed in vivo and require further characterization.
